IMUX expects pivotal Phase 3 vidofludimus calcium data by end-2026
IMUX is advancing vidofludimus calcium through pivotal Phase 3 trials in relapsing MS. Top-line data are expected by end of 2026, with a U.S. NDA submission targeted for mid-2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.